September 3, 2025 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and XWPharma Ltd. (“XWPharma”) together announced today that Avadel has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a GABAB receptor agonist, for all indications, including the treatment of sleep disorders, such as narcolepsy and idiopathic hypersomnia (“IH”). Valiloxybate has been purposef...

September 8, 2025 — Epigenic Therapeutics (About Epigenic TherapeuticsEpigenic Therapeutics is a frontier biotechnology company dedicated to developing next-generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering genetic technologies and developing gene modulation therapies, the company has multiple product candidates in the pipeline, including treatments for metabolic, cardiovascular, vi...

September 3, 2025 – VelaVigo (Shanghai) Limited (VelaVigo), a subsidiary of VelaVigo Cayman Limited and a biotech company with a robust discovery and development platform for multispecific antibodies and antibody-drug conjugates (ADCs), congratulates its partner Avenzo Therapeutics, Inc. (“Avenzo”) on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific ADC. This IND clearance f...

September 3, 2025 — Argo Biopharmaceutical Co., Ltd. (Argo Biopharma, the Company), a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics, today announced that it has entered into an additional strategic collaboration with Novartis (NYSE: NVS) for multiple cardiovascular assets in Argo’s pipeline. The new agreements are in addition to the existing collaboration between the two companies and comprise their third transaction including assets from Argo’s pi...

Nanjing, China/Gaithersburg, USA | August, 26 2025, TransThera Sciences (Nanjing), Inc. ( Biotechnology (Investable) Index.About TransTheraTransThera is a clinical demand-oriented, registrational clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design, TransThera aims to develop first-in-class or best-in-cla...

On 25 August 2025, Vibrant Therapeutics (Guangzhou) Co., Ltd. (D experts. The company focuses on the field of tumour immunotherapy and is committed to developing globally competitive first-in-class and best-in-class drugs to provide patients with better treatment options. Click here for full article.

On 21st July 2025, Suzhou Ribo Life Science Co., Ltd. ( Click here for the full article.

On July 28, VelaVigo, a global biotech company focused on novel drug discovery and development, today announced the successful closing of over US$60 million in Pre-A+ funding. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital, among others, alongside increased commitments from existing investors such as HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Ca...

TransThera Sciences (Nanjing), Inc. (s NMPA, but also secured FDA Fast Track Designation and Orphan Drug Designation, as well as EMA Orphan Drug Designation, fully showcasing its international competitiveness. Currently, Tinengotinib is undergoing Phase III registrational clinical studies in China and globally for the last-line cholangiocarcinoma indication, for which there are currently no effective treatments. It is expected to submit a new drug application in China within 2025 and has the pot...

TransThera Sciences (HKG:2617) launched its initial public offering in Hong Kong that seeks to raise up to HK$200.9 million, according to a Friday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm is offering as many as 15,281,000 shares at an indicative price of HK$13.15 each.TransThera secured five cornerstone investors, including Jiangbei Pharmaceutical, Akeso (HKG:9926), Sinohsc Honest, Pharmablock Horizon, and Kelingan, which committed to subscribe for a combined HK$130.0 mi...